盤尾絲蟲病治療市場規模、佔有率和成長分析：按藥物類型、治療類型、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球盤尾絲蟲病治療市場價值為 19.2 億美元，預計到 2025 年將成長至 20.5 億美元，到 2033 年將成長至 34.4 億美元，預測期（2026-2033 年）複合年成長率為 6.7%。

全球盤尾絲蟲病治療市場以藥物、診斷和社區治療計畫結合為特徵，旨在控制流行地區的河盲症。該疾病對當地經濟狀況造成重大影響，使弱勢族群陷入貧困。市場成長主要由捐助方資助的社區主導計畫推動，這些計畫加強了當地醫護人員的培訓，並擴大了治療範圍，特別是莫昔克丁的使用。隨著治療覆蓋率的提高，感染傳播得到控制，促使各國政府加大對國內監測和診斷系統的投入。人工智慧驅動的藥物發現和流行病管理預測分析等創新方法正在革新治療研發和病患監測。這些進步使得及時、精準的治療得以實現，並採用數據驅動的方法有效對抗受影響社區的盤尾絲蟲病。

全球盤尾絲蟲病治療市場按藥物類型、治療類型、分銷管道、最終用戶和地區進行細分。依藥物類型分類，市場分為伊維菌素、多西環素和莫昔克丁。按治療類型分類，市場分為藥物治療和聯合治療。依分銷管道分類，市場分為醫院藥房、零售藥房和公共衛生項目。依最終用戶分類，市場分為醫院、診所和社區健康中心。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球盤尾絲蟲病治療市場促進因素

全球盤尾絲蟲病治療市場主要受流行地區大規模藥物管理（MDA）工作的擴展所驅動。隨著這些工作的擴展，治療覆蓋率不斷提高，從而降低了感染率，減輕了疾病的整體臨床負擔。將治療服務整合到現有醫療基礎設施中，可以最大限度地提高營運效率，並最大限度地減少後勤方面的挑戰。此外，進行社區參與和宣傳活動可以提高目標族群的接受度和遵從性。依從性的提高反過來又會刺激對藥物的需求，並促使衛生部門購買更多預防性療法。因此，這種需求推動了市場成長，並激勵製造商投資於產能和全球分銷網路。

全球盤尾絲蟲病治療市場的限制因素

全球盤尾絲蟲病治療市場面臨許多限制因素，主要源自於流行地區基礎設施的挑戰。診所數量有限、訓練有素的醫護人員短缺以及交通路線不可靠，都阻礙了治療的持續發展。脆弱的供應鏈結構經常導致藥品缺貨和配送延誤，擾亂治療計劃並降低療效。這些基礎設施缺陷也限制了進行必要的社區宣傳活動，難以確保患者堅持治療。因此，由於衛生部門難以有效分配資源，治療產品的需求仍然低迷，這反過來又抑制了製造商擴大產能以滿足這些服務不足市場需求的動機。

全球盤尾絲蟲病治療市場趨勢

全球盤尾絲蟲病治療市場正經歷著向綜合媒介控制策略的重大轉變，相關人員優先考慮採取合作方式來對抗該疾病。各國政府和非政府組織正日益加強合作，分發經殺蟲劑處理的蚊帳，進行幼蟲防治活動，並加強社區宣傳活動，以有效減少黑蠅數量。這種綜合策略是對傳統伊維菌素療法的成本效益補充，不僅減少了對年度藥物治療的依賴，而且促進了疾病的永續管理。對預防措施的重視和對加強社區監測網路的推動，正在重塑治療方法，促進跨部門夥伴關係，並增加對社區生態學干預措施的投資，從而提高盤尾絲蟲病管理的整體有效性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球盤尾絲蟲病治療市場規模：依藥物類型分類

• 伊維菌素
• 多西環素
• 莫昔克汀

全球盤尾絲蟲病治療市場規模：依治療類型分類

• 藥物治療
• 聯合治療

全球盤尾絲蟲病治療市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 公共衛生計劃

全球盤尾絲蟲病治療市場規模：依最終用戶分類

• 醫院
• 診所
• 社區健康中心

全球盤尾絲蟲病治療市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Merck & Co., Inc.
• Bayer AG
• Johnson & Johnson
• Sanofi SA
• Pfizer Inc.
• Novartis AG
• AbbVie Inc.
• GlaxoSmithKline plc
• Astellas Pharma Inc.
• Eisai Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Dr. Reddy's Laboratories Limited
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Lupin Limited
• Aurobindo Pharma Limited
• Zydus Lifesciences Limited
• Alkem Laboratories Limited
• Emzor Pharmaceutical Industries Limited

結論與建議

Global Onchocerciasis Treatment Market size was valued at USD 1.92 Billion in 2024 and is poised to grow from USD 2.05 Billion in 2025 to USD 3.44 Billion by 2033, growing at a CAGR of 6.7% during the forecast period (2026-2033).

The global onchocerciasis treatment market is characterized by a combination of pharmaceuticals, diagnostics, and community delivery programs aimed at controlling river blindness in endemic areas, significantly impacting socioeconomic conditions by pushing vulnerable populations into poverty. Growth in this market is driven by community-directed initiatives supported by donor funding, which enhances local health workforce training and increases treatment reach, notably for moxidectin. As treatment coverage improves, transmission declines, prompting governments to invest more in domestic surveillance and diagnostics. Innovative approaches, such as AI-driven drug discovery and predictive analytics for outbreak management, are revolutionizing therapy development and patient monitoring. These advancements enable timely and targeted treatment delivery, providing a data-centric method to combat onchocerciasis effectively in the affected communities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onchocerciasis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onchocerciasis Treatment Market Segments Analysis

The global onchocerciasis treatment market is segmented by drug type, treatment type, distribution channel, end user and region. Based on drug type, the market is segmented into Ivermectin, Doxycycline and Moxidectin. Based on treatment type, the market is segmented into Drug Therapy and Combination Therapy. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Public Health Programs. Based on end user, the market is segmented into Hospitals, Clinics and Community Health Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Onchocerciasis Treatment Market

The global Onchocerciasis Treatment market is significantly driven by the scaling of mass drug administration efforts in endemic regions. As these initiatives expand, they enhance coverage, thereby reducing transmission rates and alleviating the overall clinical burden of the disease. By integrating treatment delivery into existing health infrastructure, operational efficiencies can be maximized, minimizing logistical challenges. Moreover, incorporating community engagement and education fosters greater acceptance and compliance among target populations. This increased adherence subsequently boosts demand for pharmaceuticals, prompting health authorities to procure more preventive therapies. Consequently, this demand spurs market growth and encourages manufacturers to invest in production capabilities and global distribution networks.

Restraints in the Global Onchocerciasis Treatment Market

The Global Onchocerciasis Treatment market faces significant constraints due to a variety of infrastructural challenges in endemic regions. Limited clinics, a scarcity of trained personnel, and unreliable transportation routes hinder the consistent delivery of therapies. Weak supply chain mechanisms often lead to stockouts and delays in distribution, disrupting treatment schedules and diminishing therapeutic effectiveness. These infrastructural shortcomings also restrict community outreach efforts, essential for raising awareness and ensuring patient adherence to treatment. Consequently, the demand for treatment products remains constrained, as health authorities grapple with efficient resource distribution, which in turn discourages manufacturers from expanding production capabilities for these underserved markets.

Market Trends of the Global Onchocerciasis Treatment Market

The Global Onchocerciasis Treatment market is witnessing a significant shift towards integrated vector management strategies, as stakeholders prioritize collaborative approaches to combat the disease. Governments and NGOs are increasingly aligning their efforts in delivering insecticide-treated nets, conducting larviciding activities, and enhancing community education to effectively reduce blackfly populations. This holistic strategy not only diminishes the reliance on annual drug administration but also fosters sustainable disease control, making it a cost-effective complement to traditional ivermectin therapy. The emphasis on preventive measures and strengthened regional surveillance networks is reshaping the treatment landscape, encouraging cross-sector partnerships and driving investment into localized ecological interventions, thereby enhancing the overall efficacy of onchocerciasis management.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Onchocerciasis Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Ivermectin
• Doxycycline
• Moxidectin

Global Onchocerciasis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Drug Therapy
• Combination Therapy

Global Onchocerciasis Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Public Health Programs

Global Onchocerciasis Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Community Health Centers

Global Onchocerciasis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Type, Treatment Type, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Type, Treatment Type, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Treatment Type, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Treatment Type, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Treatment Type, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emzor Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations